Nephrogen
Nephrogen is a biotech company commercializing an AI-driven curative medicine platform focused on kidney and pancreatic diseases. Their NeFINDTM platform uses artificial intelligence and high-throughput in vivo screening to engineer novel gene delivery vectors that are 10-100X more efficient, cheaper, and less immunogenic than existing vectors. The company aims to solve delivery challenges in genomic medicines to improve longevity and quality of life for 50 million Americans. Nephrogen is a spin-out from Stanford and Harvard, co-founded by experts in computational biology, nephrology, and genetics. Their business model centers on developing curative genomic medicines for difficult-to-treat diseases, leveraging advanced AI and gene therapy technologies to create novel treatments with significant market potential.
Nephrogen
Nephrogen is a biotech company commercializing an AI-driven curative medicine platform focused on kidney and pancreatic diseases. Their NeFINDTM platform uses artificial intelligence and high-throughput in vivo screening to engineer novel gene delivery vectors that are 10-100X more efficient, cheaper, and less immunogenic than existing vectors. The company aims to solve delivery challenges in genomic medicines to improve longevity and quality of life for 50 million Americans. Nephrogen is a spin-out from Stanford and Harvard, co-founded by experts in computational biology, nephrology, and genetics. Their business model centers on developing curative genomic medicines for difficult-to-treat diseases, leveraging advanced AI and gene therapy technologies to create novel treatments with significant market potential.